IL308378A - A pyridazine compound for NLRP3 inhibition - Google Patents

A pyridazine compound for NLRP3 inhibition

Info

Publication number
IL308378A
IL308378A IL308378A IL30837823A IL308378A IL 308378 A IL308378 A IL 308378A IL 308378 A IL308378 A IL 308378A IL 30837823 A IL30837823 A IL 30837823A IL 308378 A IL308378 A IL 308378A
Authority
IL
Israel
Prior art keywords
pyridazine compounds
inhibiting nlrp3
nlrp3
inhibiting
pyridazine
Prior art date
Application number
IL308378A
Other languages
English (en)
Hebrew (he)
Inventor
St?phane DORICH
Jason Burch
Miguel St-Onge
Amandine Chefson
Alexandre C?T?
Ramsay Beveridge
St?Phane Ciblat
Original Assignee
Ventus Therapeutics U S Inc
St?phane DORICH
Jason Burch
St Onge Miguel
Amandine Chefson
Alexandre C?T?
Ramsay Beveridge
St?Phane Ciblat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc, St?phane DORICH, Jason Burch, St Onge Miguel, Amandine Chefson, Alexandre C?T?, Ramsay Beveridge, St?Phane Ciblat filed Critical Ventus Therapeutics U S Inc
Publication of IL308378A publication Critical patent/IL308378A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL308378A 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition IL308378A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171932P 2021-04-07 2021-04-07
US17/528,928 US11319319B1 (en) 2021-04-07 2021-11-17 Compounds for inhibiting NLRP3 and uses thereof
PCT/US2022/023893 WO2022216971A1 (en) 2021-04-07 2022-04-07 Pyridazine compounds for inhibiting nlrp3

Publications (1)

Publication Number Publication Date
IL308378A true IL308378A (en) 2024-01-01

Family

ID=81385286

Family Applications (2)

Application Number Title Priority Date Filing Date
IL307303A IL307303A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition
IL308378A IL308378A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL307303A IL307303A (en) 2021-04-07 2022-04-07 A pyridazine compound for NLRP3 inhibition

Country Status (15)

Country Link
US (10) US11319319B1 (enExample)
EP (3) EP4320102A1 (enExample)
JP (2) JP7620120B2 (enExample)
KR (1) KR20230167394A (enExample)
CN (2) CN117500792A (enExample)
AU (3) AU2022256052B2 (enExample)
BR (1) BR112023020483A2 (enExample)
CA (1) CA3214676A1 (enExample)
CL (2) CL2023002973A1 (enExample)
CO (1) CO2023013356A2 (enExample)
IL (2) IL307303A (enExample)
MX (2) MX2023011576A (enExample)
PE (1) PE20240765A1 (enExample)
TW (1) TW202304905A (enExample)
WO (1) WO2022216971A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022253936A1 (en) 2021-06-04 2022-12-08 F. Hoffmann-La Roche Ag Triazine derivatives and their use in the treatment of cancer.
US20240294542A1 (en) * 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
WO2023275366A1 (en) * 2021-07-02 2023-01-05 Astrazeneca Ab Nlrp3 inflammasome inhibitors
IL310264A (en) 2021-07-21 2024-03-01 Nico Therapeutics Inc Annulated pyridazine compound
AU2022334474A1 (en) * 2021-08-25 2024-03-14 Ptc Therapeutics, Inc. Inhibitors of nlrp3
AU2022355409B2 (en) * 2021-09-30 2025-10-16 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
EP4421068A1 (en) * 2021-10-22 2024-08-28 Zhejiang Aixplorer Biotech Co., Ltd. Nitrogen-containing compound, preparation method therefor and application thereof
JP2025510414A (ja) * 2022-03-25 2025-04-14 ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体
JP2025511199A (ja) * 2022-03-31 2025-04-15 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド Ｎｌｒｐ３インフラマソーム阻害剤
WO2024013395A1 (en) * 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
US20240124451A1 (en) 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
JP2025023868A (ja) * 2022-09-23 2025-02-17 メルク・シャープ・アンド・ドーム・エルエルシー Ｎｏｄ様受容体タンパク質３の阻害剤として有用なフタラジン誘導体
WO2024090469A1 (ja) 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
TW202419449A (zh) * 2022-10-31 2024-05-16 美商凡特斯治療美國公司 可用作ｎｌｒｐ３抑制劑之橋接雙環雜環烷基吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
IL320499A (en) * 2022-11-04 2025-06-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and use thereof
WO2024109922A1 (zh) * 2022-11-25 2024-05-30 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
EP4637746A1 (en) * 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2024140704A1 (zh) * 2022-12-27 2024-07-04 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
TW202440107A (zh) 2022-12-28 2024-10-16 瑞典商阿斯特捷利康公司 Ｎｌｒｐ３炎症小體抑制劑
CN120418236A (zh) * 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
WO2024141534A1 (en) 2022-12-28 2024-07-04 Astrazeneca Ab Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds
EP4656635A1 (en) 2023-01-24 2025-12-03 Daiichi Sankyo Company, Limited Substituted benzene compound
KR20250152599A (ko) 2023-01-31 2025-10-23 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 [1,2,4]트라이아졸로[4,3-a]피리딘 및 [1,2,4]트라이아졸로[4,3-a]피라진
KR20250151413A (ko) 2023-01-31 2025-10-21 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 이미다조[1,2-d][1,2,4]트라이아진
AU2024215094A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
KR20250152598A (ko) 2023-01-31 2025-10-23 얀센 파마슈티카 엔브이 Nlrp3 억제제로서의 2-(피리다진-3-일)-5-(트라이플루오로메틸)페놀
CN120435466A (zh) * 2023-02-17 2025-08-05 成都赜灵生物医药科技有限公司 六元氮杂环类化合物及其用途
WO2024217462A1 (zh) * 2023-04-18 2024-10-24 南京明德新药研发有限公司 五氟化硫取代的芳环化合物及其应用
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
WO2025006681A2 (en) * 2023-06-27 2025-01-02 Viva Star Biosciences (Us) Inc. Substituted pyridazine compounds as inhibitors of nlrp3 activity and therapeutic uses thereof
TW202506132A (zh) * 2023-08-11 2025-02-16 大陸商藥捷安康(南京)科技股份有限公司 Nlrp3炎症小體抑制劑及其應用
CN117143027B (zh) * 2023-08-31 2024-12-20 四川大学 3-苄氧基-6-羟苯基哒嗪类化合物及其制备方法和用途
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
WO2025059481A1 (en) * 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Solid forms of an nlrp3 inhibitor and uses thereof
US20250163060A1 (en) * 2023-11-20 2025-05-22 Ventus Therapeutics U.S., Inc. Solid freebase forms of 5-chloro-2-(4-((2-hydroxy-2-methylpropyl)amino)pyrido[3,4-d]pyridazin-1-yl)phenol for inhibiting nlrp3 and uses thereof
WO2025128781A1 (en) 2023-12-14 2025-06-19 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
TW202535370A (zh) 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303061A (enExample) * 1969-05-03 1973-01-17
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB2063249A (en) * 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1989011279A1 (en) 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
EP0449203B1 (en) 1990-03-30 1994-12-07 Mitsubishi Chemical Corporation 4-Phenylphthalazine derivatives
JPH03284669A (ja) * 1990-03-30 1991-12-16 Mitsubishi Kasei Corp ４―フェニルフタラジン誘導体
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
WO1993015058A1 (en) 1992-01-23 1993-08-05 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
DE4417746A1 (de) 1994-05-20 1995-11-23 Bayer Ag Neue Farbstoffe zum Massefärben von Kunststoffen
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6288064B1 (en) 1996-08-20 2001-09-11 Eisai Co., Ltd. Remedy for erection failure comprising fused pyridazine compound
US20030124053A1 (en) 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
CA2275686C (en) 1996-12-18 2006-10-17 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
US6486158B1 (en) 1998-08-14 2002-11-26 Cell Pathways, Inc. [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
AU765128B2 (en) 1999-03-22 2003-09-11 Bristol-Myers Squibb Company Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
RU2004116320A (ru) 2001-11-30 2005-10-10 Пфайзер Продактс Инк. (Us) Арилконденсированные азаполициклические соединения
US20040242886A1 (en) 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
WO2005016000A1 (en) 2003-08-05 2005-02-24 Avalon Pharmaceuticals Derivatives of cyclic quinone and uses thereof
US7087621B2 (en) 2003-09-05 2006-08-08 Bristol-Myers Squibb Company Benzo- and azabenzodithiazole compounds
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
CN1984904A (zh) 2004-05-08 2007-06-20 神经能质公司 3－芳基－5,6－二取代哒嗪
CA2569849C (en) 2004-06-09 2012-11-27 Erick M. Carreira Monophosphine compounds, transition metal complexes thereof and production of optically active compounds using the complexes as asymmetric catalysts
US20060156485A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2006090273A2 (en) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
AU2006295397A1 (en) 2005-09-23 2007-04-05 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
FR2891828B1 (fr) 2005-10-12 2007-12-21 Sanofi Aventis Sa Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
AU2006311767A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
EP1948656A2 (en) 2005-11-03 2008-07-30 Ilypsa, Inc. Azaindole compounds and use thereof as phospholipase-a2 inhibitors
WO2007056580A2 (en) 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
JP2009120486A (ja) 2005-12-05 2009-06-04 Mitsubishi Pharma Corp 核内オーファン受容体の新規活性化剤及びその用途
HUE028504T2 (en) 2006-01-23 2016-12-28 Amgen Inc Aurora kinase modulators and method for their application
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
NZ570099A (en) 2006-02-16 2010-08-27 Syngenta Participations Ag Pesticides containing a bicyclic bisamide structure
AU2007283401A1 (en) 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR068072A1 (es) 2007-04-19 2009-11-04 Novartis Ag Derivados de bencimidazoles, composiciones farmaceuticas y usos
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
US9023490B2 (en) 2007-06-15 2015-05-05 Versitech Limited Extended pi-conjugated platinum (II) complexes
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
US20090082358A1 (en) 2007-09-20 2009-03-26 Nobuko Nishimura Vanilloid receptor ligands and their use in treatments
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
CA2709918A1 (en) 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US8445473B2 (en) 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
WO2009140163A1 (en) 2008-05-15 2009-11-19 Merck & Co., Inc. Oxazolobenzimidazole derivatives
DK2285786T3 (da) 2008-06-16 2013-11-04 Merck Patent Gmbh Quinoxalindion-derivater
WO2009157386A1 (ja) 2008-06-25 2009-12-30 住友化学株式会社 光学活性アミン化合物の製造方法
EP2318401A4 (en) 2008-08-16 2013-10-30 Genentech Inc AZAINDOLI INHIBITORS OF IPA
AU2009296931A1 (en) 2008-09-26 2010-04-01 Merck Sharp & Dohme Corp. Oxazolobenzimidazole derivatives
EA201171098A1 (ru) 2009-03-02 2012-04-30 Сертрис Фармасьютикалз, Инк. 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
BRPI1006543A2 (pt) 2009-04-01 2015-08-25 Basf Se "compostos de isoxazolina, composição agrícola, composição veterinária, uso de composto, método para o controle de pragas invertebradas, material de propagação de plantas e método para o tratamento, controle, prevenção ou proteção de animais contra infestação ou infecção por parasitas"
EP2417133A1 (en) 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Compounds and methods for antiviral treatment
EP2416772A1 (en) 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
UY32742A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US20110152246A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102958930B (zh) 2010-06-28 2018-04-27 默克专利有限公司 作为用于对抗癌症的激酶抑制剂的2,4-二芳基取代的[1,8]二氮杂萘化合物
EP2588473A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
CA2812088A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2709983B1 (en) 2011-05-18 2018-04-18 Syngenta Participations AG Insecticidal compounds based on arylthioacetamide derivatives
US8912202B2 (en) 2011-08-08 2014-12-16 Merck Patent Gmbh N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
WO2013026939A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Methods for the control of termites and ants
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AU2012381042B2 (en) 2012-05-22 2015-10-01 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
WO2014079941A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on n-(arylsulfanylmethyl) carboxamide derivatives
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014079935A1 (en) 2012-11-21 2014-05-30 Syngenta Participations Ag Insecticidal compounds based on arylthioacetamide derivatives
WO2014086737A1 (de) 2012-12-06 2014-06-12 Bayer Cropscience Ag Kondensierte 2-pyridon-3-carboxamide und ihre verwendung als herbizide
TW201439060A (zh) 2013-02-27 2014-10-16 Sunshine Lake Pharma Co Ltd 作爲丙型肝炎抑制劑的橋環化合物及其藥物組合物和用途
GB201311953D0 (en) 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
UY35809A (es) 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
BR112016023117B1 (pt) 2014-04-04 2023-02-07 Pfizer Inc Compostos de heteroarila ou arila bicíclicos fundidos
CN103992311B (zh) 2014-06-20 2017-01-25 东南大学 Hedgehog信号通路抑制剂
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
JP6771464B2 (ja) 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
RU2021100040A (ru) 2014-12-22 2021-02-02 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
WO2016123796A1 (en) 2015-02-06 2016-08-11 Abbvie Inc. Substituted phthalazines
IL253661B2 (en) 2015-02-16 2024-01-01 Univ Queensland Sulfonylureas bearing a five-membered ring, and pharmaceutical compositions and uses thereof
MX382671B (es) 2015-12-10 2025-03-13 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
KR20180119582A (ko) 2016-02-12 2018-11-02 파맥시스 엘티디 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
ES2940611T3 (es) 2016-04-18 2023-05-09 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
EP3236267B1 (en) 2016-04-18 2021-09-08 Roche Diagnostics GmbH Decapper and apparatus
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
WO2018031680A1 (en) 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
WO2018080216A1 (en) * 2016-10-28 2018-05-03 Daewoong Pharmaceutical Co., Ltd. Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CN110612294B (zh) 2017-01-31 2024-01-16 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2018172925A1 (en) 2017-03-23 2018-09-27 Vitas Pharma Research Pvt Ltd Inhibitors of dna gyrase for treatment of bacterial infections
KR101943428B1 (ko) 2017-03-24 2019-01-30 엘티소재주식회사 유기 발광 소자 및 유기 발광 소자의 유기물층용 조성물
WO2018174678A1 (ko) 2017-03-24 2018-09-27 희성소재(주) 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
WO2018221433A1 (ja) 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
US11530225B2 (en) 2017-07-20 2022-12-20 Lg Chem, Ltd. Compound and organic light-emitting diode comprising same
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
ES2940408T3 (es) 2017-08-21 2023-05-08 Merck Patent Gmbh Derivados de benzoimidazol como antagonistas de los receptores de adenosina
CN110526898A (zh) 2018-05-25 2019-12-03 北京诺诚健华医药科技有限公司 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
WO2020021015A1 (en) 2018-07-26 2020-01-30 Esteve Pharmaceuticals, S.A. New imidazopyridine derivatives for treating pain and pain related conditions
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN114007614A (zh) 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR102721075B1 (ko) 2019-02-15 2024-10-24 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US20230107277A1 (en) * 2020-03-27 2023-04-06 Astellas Pharma Inc. Substituted pyridazine compound
CA3177672A1 (en) 2020-05-28 2021-12-02 Michael Eric MURATORE Compounds
KR20230040386A (ko) 2020-06-09 2023-03-22 파르데스 바이오사이언시스, 인크. 시스테인 프로테아제의 억제제 및 이의 사용 방법
TW202231281A (zh) 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US20240166610A1 (en) 2021-02-08 2024-05-23 Medshine Discovery Inc. Substituted pyridazine phenol derivatives
KR20230167071A (ko) 2021-04-07 2023-12-07 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 (usp1)의 억제
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
EP4345097A4 (en) 2021-04-28 2025-04-23 Astellas Pharma Inc. SUBSTITUTED TRIAZINE COMPOUND
CN117279899A (zh) 2021-04-29 2023-12-22 詹森药业有限公司 作为nlrp3炎性小体抑制剂的酞嗪酮衍生物
DK4337652T3 (da) 2021-05-12 2025-06-10 Hoffmann La Roche NLRP3-hæmmere
WO2022253936A1 (en) 2021-06-04 2022-12-08 F. Hoffmann-La Roche Ag Triazine derivatives and their use in the treatment of cancer.
US20240294542A1 (en) 2021-06-05 2024-09-05 Transthera Sciences (Nanjing), Inc. Nlrp3 inflammasome inhibitor and application thereof
WO2023278438A1 (en) 2021-06-29 2023-01-05 Zomagen Biosciences Ltd Nlrp3 modulators
WO2023275366A1 (en) 2021-07-02 2023-01-05 Astrazeneca Ab Nlrp3 inflammasome inhibitors
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
IL310264A (en) 2021-07-21 2024-03-01 Nico Therapeutics Inc Annulated pyridazine compound
KR20240052009A (ko) 2021-08-25 2024-04-22 자이두스 라이프사이언시즈 리미티드 신경염증성 장애의 치료
WO2023028536A1 (en) 2021-08-25 2023-03-02 Ptc Therapeutics, Inc. 1,2,4-triazine derivatives useful as inhibitors of nlrp3
AU2022334474A1 (en) 2021-08-25 2024-03-14 Ptc Therapeutics, Inc. Inhibitors of nlrp3
AU2022355409B2 (en) 2021-09-30 2025-10-16 Origiant Pharmaceutical Co., Ltd. Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative
EP4419532A1 (en) 2021-10-19 2024-08-28 F. Hoffmann-La Roche AG Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors
EP4421068A1 (en) 2021-10-22 2024-08-28 Zhejiang Aixplorer Biotech Co., Ltd. Nitrogen-containing compound, preparation method therefor and application thereof
WO2023088856A1 (en) 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
JP2024540525A (ja) 2021-11-19 2024-10-31 エフ． ホフマン－ラ ロシュ アーゲー Ｎｌｒｐ３の阻害剤としてのピリダジン誘導体
WO2023129987A1 (en) 2021-12-29 2023-07-06 Neumora Therapeutics, Inc. Pyridazine derivatives as modulators of nlrp3 inflammasome and related methods
EP4461729A1 (en) 2022-01-07 2024-11-13 Transthera Sciences (Nanjing), Inc. Antigen binding protein targeting msln and use thereof
CN116726020A (zh) 2022-03-08 2023-09-12 上海拓界生物医药科技有限公司 一类含哒嗪的化合物的药物组合物及其医药用途
GEAP202516611A (en) 2022-03-15 2025-01-27 Zomagen Biosciences Ltd Nlrp3 modulators
JP2025510414A (ja) 2022-03-25 2025-04-14 ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体
JP2025511199A (ja) 2022-03-31 2025-04-15 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド Ｎｌｒｐ３インフラマソーム阻害剤
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
CN116969920A (zh) 2022-04-29 2023-10-31 上海辉启生物医药科技有限公司 稠合哒嗪衍生物及其制备方法与医药用途
US20230365534A1 (en) 2022-05-13 2023-11-16 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
US20250353830A1 (en) 2022-06-03 2025-11-20 Hoffmann-La Roche Inc. Novel compounds
WO2024006559A1 (en) 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
CN119546599A (zh) 2022-07-14 2025-02-28 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用
EP4558499A1 (en) 2022-07-21 2025-05-28 F. Hoffmann-La Roche AG Nlrp3 inhibitors
IL318406A (en) 2022-07-28 2025-03-01 Ac Immune Sa New compounds
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
CN116789674B (zh) 2022-08-24 2024-05-24 杭州高光制药有限公司 Nlrp3炎性小体抑制剂
US20240124451A1 (en) 2022-09-23 2024-04-18 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2024090469A1 (ja) 2022-10-26 2024-05-02 アステラス製薬株式会社 縮環ピリダジン誘導体
TW202419449A (zh) 2022-10-31 2024-05-16 美商凡特斯治療美國公司 可用作ｎｌｒｐ３抑制劑之橋接雙環雜環烷基吡啶并－〔３，４－ｄ〕噠嗪胺衍生物
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4611743A1 (en) 2022-11-02 2025-09-10 Merck Sharp & Dohme LLC Triazines useful as inhibitors of nod-like receptor protein 3
IL320499A (en) 2022-11-04 2025-06-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and use thereof
WO2024094150A1 (en) 2022-11-04 2024-05-10 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
CA3268380A1 (en) 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag TRIAZINONE DERIVATIVES USED AS NLRP3 INHIBITORS
WO2024099993A1 (en) 2022-11-09 2024-05-16 F. Hoffmann-La Roche Ag Triazinone derivatives as nlrp3 inhibitors
KR20250093508A (ko) 2022-11-09 2025-06-24 에프. 호프만-라 로슈 아게 Nlrp3 억제제로서의 트리아지논 유도체
CN118056822A (zh) 2022-11-18 2024-05-21 正大天晴药业集团股份有限公司 一种哒嗪并环化合物及其用途
WO2024109922A1 (zh) 2022-11-25 2024-05-30 成都赜灵生物医药科技有限公司 桥环并哒嗪类化合物及其用途
EP4630417A1 (en) 2022-12-07 2025-10-15 F. Hoffmann-La Roche AG Novel compounds as modulators of nlrp3 inhibition
CN120303272A (zh) 2022-12-08 2025-07-11 豪夫迈·罗氏有限公司 Nlrp3的抑制剂
EP4637746A1 (en) 2022-12-19 2025-10-29 Merck Sharp & Dohme LLC 6,6 bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
EP4638434A1 (en) 2022-12-23 2025-10-29 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
WO2024140704A1 (zh) 2022-12-27 2024-07-04 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
CN120418236A (zh) 2022-12-28 2025-08-01 长春金赛药业有限责任公司 哒嗪类nlrp3抑制剂化合物、药物组合物及其制备方法和应用
TW202440107A (zh) 2022-12-28 2024-10-16 瑞典商阿斯特捷利康公司 Ｎｌｒｐ３炎症小體抑制劑
AU2023414924A1 (en) 2022-12-30 2025-07-03 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds as inhibitors of nlrp3
CN120813345A (zh) 2023-01-03 2025-10-17 科达制药 作为nlrp3抑制剂的有机化合物
KR20250152599A (ko) 2023-01-31 2025-10-23 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 [1,2,4]트라이아졸로[4,3-a]피리딘 및 [1,2,4]트라이아졸로[4,3-a]피라진
KR20250152598A (ko) 2023-01-31 2025-10-23 얀센 파마슈티카 엔브이 Nlrp3 억제제로서의 2-(피리다진-3-일)-5-(트라이플루오로메틸)페놀
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
KR20250151413A (ko) 2023-01-31 2025-10-21 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 이미다조[1,2-d][1,2,4]트라이아진
AU2024215094A1 (en) 2023-01-31 2025-09-11 Janssen Pharmaceutica Nv Pyridin-2(1h)-ones and pyrimidin-4(3h)-ones as nlrp3 inhibitors

Also Published As

Publication number Publication date
TW202330522A (zh) 2023-08-01
CN117500792A (zh) 2024-02-02
EP4537900A2 (en) 2025-04-16
US20240174668A1 (en) 2024-05-30
US20240368160A1 (en) 2024-11-07
TW202304905A (zh) 2023-02-01
AU2022256052B2 (en) 2025-06-05
MX2023011576A (es) 2023-11-09
CL2023002973A1 (es) 2024-03-08
EP4331668A3 (en) 2024-06-05
EP4331668A2 (en) 2024-03-06
KR20230167394A (ko) 2023-12-08
JP7620120B2 (ja) 2025-01-22
US20230159526A1 (en) 2023-05-25
AU2023263450A1 (en) 2023-11-23
CN117510495A (zh) 2024-02-06
MX2024000820A (es) 2024-02-06
JP2024514837A (ja) 2024-04-03
WO2022216971A9 (en) 2022-12-08
EP4320102A1 (en) 2024-02-14
US11319319B1 (en) 2022-05-03
CA3214676A1 (en) 2022-10-13
IL307303A (en) 2023-11-01
US20240158396A1 (en) 2024-05-16
BR112023020483A2 (pt) 2023-11-21
AU2023263450B2 (en) 2025-04-17
CO2023013356A2 (es) 2023-10-30
EP4537900A3 (en) 2025-07-16
US20240199606A1 (en) 2024-06-20
PE20240765A1 (es) 2024-04-17
US20220340567A1 (en) 2022-10-27
AU2025213656A1 (en) 2025-08-28
US12312350B2 (en) 2025-05-27
US12410167B2 (en) 2025-09-09
AU2022256052A1 (en) 2023-11-16
US12441728B2 (en) 2025-10-14
AU2023263450C1 (en) 2025-10-30
US20250250270A1 (en) 2025-08-07
US20240360128A1 (en) 2024-10-31
CL2024001964A1 (es) 2024-12-06
US20240360129A1 (en) 2024-10-31
US12281112B2 (en) 2025-04-22
US12351578B2 (en) 2025-07-08
JP2024050527A (ja) 2024-04-10
WO2022216971A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
IL308378A (en) A pyridazine compound for NLRP3 inhibition
IL316450A (en) Compounds for inhibiting KIF18A
GB201914860D0 (en) Inhibitor compounds
GB202008201D0 (en) Inhibitor compounds
IL290087A (en) inhibitory substances
GB202200735D0 (en) Compounds
GB202004960D0 (en) Inhibitor compounds
IL288292A (en) Oxathiazine compounds for gapdh inhibition
GB202208643D0 (en) Compounds
GB201905328D0 (en) Inhibitor compounds
HK40101148A (en) Pyridazine compounds for inhibiting nlrp3
GB202110373D0 (en) Inhibitor compounds
GB202208151D0 (en) Compounds
GB202201996D0 (en) Compounds
GB202117224D0 (en) Inhibitor compounds
GB202112240D0 (en) Inhibitor compounds
GB202107325D0 (en) Inhibitor compounds
GB202104781D0 (en) Inhibitor compounds
GB202016964D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
GB202008205D0 (en) Inhibitor compounds
GB202307924D0 (en) Inhibitor compounds
GB202306601D0 (en) Inhibitor compounds
GB202300881D0 (en) Inhibitor compounds
GB202215245D0 (en) Inhibitor compounds